Drug intelligence / Profile preview

CHAGE-201-IPF

Development stage: Unknown
Lead developer: CHA Biotech
Modality: Gene Therapies, Stem Cell Therapies → Cell Therapies

Overview

**CHAGE-201-IPF** is an investigational allogeneic gene-engineered mesenchymal stem cell therapy being developed by CHA for **idiopathic pulmonary fibrosis** and other fibrotic lung diseases. Based on CHA Biotech's pipeline, it is an off-the-shelf gene-engineered MSC cell therapy program in **Phase 1/2**. The precise transgene or engineered therapeutic factor has not been publicly specified in the provided source material, but the program appears intended to use modified MSCs to deliver antifibrotic and tissue-reparative activity in the lung. The product is positioned within CHA's global allogeneic regenerative medicine pipeline and has been noted as a program with US IND activity.

Other names: CHAGE-201CHAGE201CHAGE 201allogeneic gene-engineered MSC therapy

Beyond the preview

Go deeper on CHAGE-201-IPF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHAGE-201-IPF.

Explore the full profile